Agonists targeting co-stimulatory immune-checkpoint receptors such as CD40 and OX40 have shown potential in increasing antitumor immunity in HCC to convert tumors from cold to hot phenotypes. This evidence concerns the gene TNFRSF4 and hepatocellular carcinoma.